May 19 (SeeNews) - North Macedonia-based drug maker Replek [MSE:REPL] said that its non-consolidated net profit grew 32% on the year to 110.7 million denars ($1.9 million/1.8 million euro) in the first quarter of 2020, backed by higher revenue.
Replek's operating revenue rose 40.8% to 32.4 million denars in the January-March period, the company said in an interim financial statement last week.
Sales revenues, all from domestic sales, added 39% to 31.1 million denars. Other operating revenue soared to 1.3 million denars in this year's first quarter from 603,000 denars in the same period of last year.
The company's operating expenses increased by 30.8% to 29.5 million denars, as cost of trading goods sold rose by 39% to 21.9 million denars.
Replek's shares last traded on the Macedonian stock exchange on April 15 at an average price of 80,510 denars.
(1 euro = 61.98 denars)